Literature DB >> 34251481

[MRI-guided minimally invasive treatment of prostate cancer].

Fabian Tollens1, Niklas Westhoff2, Jost von Hardenberg2, Sven Clausen3, Michael Ehmann3, Frank G Zöllner4, Anne Adlung4, Dominik F Bauer4, Stefan O Schoenberg1, Dominik Nörenberg5.   

Abstract

CLINICAL/METHODOLOGICAL ISSUE: Multiparametric magnetic resonance imaging (mpMRI) of the prostate plays a crucial role in the diagnosis and local staging of primary prostate cancer. STANDARD RADIOLOGICAL
METHODS: Image-guided biopsy techniques such as MRI-ultrasound fusion not only allow guidance for targeted tissue sampling of index lesions for diagnostic confirmation, but also improve the detection of clinically significant prostate cancer. METHODOLOGICAL INNOVATIONS: Minimally invasive, focal therapies of localized prostate cancer complement the treatment spectrum, especially for low- and intermediate-risk patients. PERFORMANCE: In patients of low and intermediate risk, MR-guided, minimally invasive therapies could enable local tumor control, improved functional outcomes and possible subsequent therapy escalation. Further study results related to multimodal approaches and the application of artificial intelligence (AI) by machine and deep learning algorithms will help to leverage the full potential of focal therapies for prostate cancer in the upcoming era of precision medicine. ACHIEVEMENTS: Completion of ongoing randomized trials comparing each minimally invasive therapy approach with established whole-gland procedures is needed before minimally invasive therapies can be implemented into existing treatment guidelines. PRACTICAL RECOMMENDATIONS: This review article highlights minimally invasive therapies of prostate cancer and the key role of mpMRI for planning and conducting these therapies.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Artificial intelligence; Focal therapy; Minimally invasive therapy; Multiparametric magnetic resonance imaging; Prostate neoplasms

Mesh:

Year:  2021        PMID: 34251481     DOI: 10.1007/s00117-021-00883-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback.

Authors:  Rajiv Chopra; Kee Tang; Mathieu Burtnyk; Aaron Boyes; Linda Sugar; Sree Appu; Laurence Klotz; Michael Bronskill
Journal:  Phys Med Biol       Date:  2009-04-08       Impact factor: 3.609

2.  A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging-Only Planning for External Beam Radiation Therapy.

Authors:  David Bird; Ann M Henry; David Sebag-Montefiore; David L Buckley; Bashar Al-Qaisieh; Richard Speight
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-07-02       Impact factor: 7.038

3.  Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.

Authors:  David Bonekamp; M B Wolf; M C Roethke; S Pahernik; B A Hadaschik; G Hatiboglu; T H Kuru; I V Popeneciu; J L Chin; M Billia; J Relle; J Hafron; K R Nandalur; R M Staruch; M Burtnyk; M Hohenfellner; H-P Schlemmer
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

Review 4.  What is still needed to make focal therapy an accepted segment of standard therapy?

Authors:  Willemien van den Bos; Berrend G Muller; Behfar Ehdaie; Peter Scardino; Jean J M C H de la Rosette
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

5.  The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.

Authors:  Simon R J Bott; Hashim U Ahmed; Richard G Hindley; Ahmad Abdul-Rahman; Alex Freeman; Mark Emberton
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

6.  Focal irreversible electroporation as primary treatment for localized prostate cancer.

Authors:  Willemien van den Bos; Matthijs J Scheltema; Amila R Siriwardana; Anton M F Kalsbeek; James E Thompson; Francis Ting; Maret Böhm; Anne-Maree Haynes; Ron Shnier; Warick Delprado; Phillip D Stricker
Journal:  BJU Int       Date:  2017-09-04       Impact factor: 5.588

7.  Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade.

Authors:  Lars Budäus; Jan Spethmann; Hendrik Isbarn; Jan Schmitges; Laura Beesch; Alexander Haese; Georg Salomon; Thorsten Schlomm; Margit Fisch; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber
Journal:  BJU Int       Date:  2011-01-18       Impact factor: 5.588

8.  MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans.

Authors:  Rajiv Chopra; Alexandra Colquhoun; Mathieu Burtnyk; William A N'djin; Ilya Kobelevskiy; Aaron Boyes; Kashif Siddiqui; Harry Foster; Linda Sugar; Masoom A Haider; Michael Bronskill; Laurence Klotz
Journal:  Radiology       Date:  2012-08-28       Impact factor: 11.105

9.  68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU.

Authors:  Irene A Burger; Julian Müller; Olivio F Donati; Daniela A Ferraro; Michael Messerli; Benedikt Kranzbühler; Edwin E G W Ter Voert; Urs J Muehlematter; Niels J Rupp; Ashkan Mortezavi; Daniel Eberli
Journal:  J Nucl Med       Date:  2019-01-25       Impact factor: 10.057

10.  Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.

Authors:  Willemien van den Bos; Berrend G Muller; Hashim Ahmed; Chris H Bangma; Eric Barret; Sebastien Crouzet; Scott E Eggener; Inderbir S Gill; Steven Joniau; Gyoergy Kovacs; Sascha Pahernik; Jean J de la Rosette; Olivier Rouvière; Georg Salomon; John F Ward; Peter T Scardino
Journal:  Eur Urol       Date:  2014-01-13       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.